Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2013 | short review | Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2013
Autoren:
Thomas Melchardt, Lukas Weiss, Richard Greil, MD Priv. Doz. Alexander Egle

Abstract

Modern treatment strategies have resulted in an excellent overall survival in the majority of patients with Hodgkin’s lymphoma. PET-stratification is used to guide treatment in patients with limited disease in clinical trials, but recent results indicate that combined treatment with chemotherapy and radiotherapy is still the standard of care. Prediction of treatment related mortality and new data about chemotherapy induced infertility will guide our decisions especially in patients with advanced disease and brentuximab vedotin is now an approved option in patients with relapsed or refractory disease.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe